Stocks
Amgen Blows Past Analysts' Expectations in Q2 CY2026 Earnings Report
Amgen (NASDAQ: AMGN) delivered strong second-quarter CY2026 numbers, exceeding Wall Street's revenue expectations. The biotechnology company reported sales of $10.05 billion, a 9.5% year-on-year increase from the same quarter last year.
The company's full-year revenue guidance of $38.8 billion at the midpoint came in 2.8% above analysts' estimates, while its non-GAAP profit of $6.29 per share was 12% above consensus estimates.
Amgen's chairman and chief executive officer, Robert A. Bradway, stated that the company's results demonstrate strong performance across its business, with six key growth drivers growing 26% year over year, generating nearly 70% of second-quarter product sales.